KNSA Logo

Kiniksa Pharmaceuticals, Ltd. (KNSA) 

NASDAQ
Market Cap
$1.66B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
596 of 776
Rank in Industry
320 of 433

Largest Insider Buys in Sector

KNSA Stock Price History Chart

KNSA Stock Performance

About Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell …

Insider Activity of Kiniksa Pharmaceuticals, Ltd.

Over the last 12 months, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $13.38M worth of Kiniksa Pharmaceuticals, Ltd. stock.

On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $8.63M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.

List of Insider Buy and Sell Transactions, Kiniksa Pharmaceuticals, Ltd.

2024-10-15SaleCHIEF OPERATING OFFICER
17,000
0.0268%
$26.87$456,790-14.01%
2024-09-23SaleCHIEF OPERATING OFFICER
17,500
0.0249%
$24.99$437,325+1.38%
2024-09-03SaleCHIEF MEDICAL OFFICER
60,692
0.0855%
$26.12$1.58M-3.88%
2024-09-03SaleCHIEF COMMERCIAL OFFICER
68,506
0.0966%
$26.12$1.79M-3.88%
2024-08-27SaleCHIEF OPERATING OFFICER
17,500
0.0244%
$26.91$470,925-6.65%
2024-07-23SaleCHAIRMAN & CEO
136,124
0.1877%
$25.65$3.49M+1.00%
2024-07-23SaleCHIEF MEDICAL OFFICER
22,000
0.0311%
$26.32$578,966-1.54%
2024-07-23SaleCHIEF FINANCIAL OFFICER
24,248
0.0323%
$24.79$601,108+4.52%
2024-03-07SaleCHAIRMAN & CEO
65,012
0.0919%
$21.02$1.37M-4.84%
2024-03-06SaleCHAIRMAN & CEO
5,582
0.008%
$21.00$117,222-3.43%
2024-03-04SaleCHAIRMAN & CEO
12,742
0.0194%
$21.49$273,834+0.35%
2024-03-01SaleCHIEF OPERATING OFFICER
1,189
0.0017%
$22.03$26,194-6.95%
2024-03-01SaleCHIEF MEDICAL OFFICER
18,844
0.0269%
$21.77$410,234-6.95%
2024-03-01SaleCHIEF ACCOUNTING OFFICER
9,659
0.0136%
$21.45$207,186-6.95%
2024-02-28SaleCHIEF ACCOUNTING OFFICER
5,126
0.0078%
$21.79$111,696-0.32%
2024-02-27SaleCHIEF MEDICAL OFFICER
10,156
0.0145%
$21.03$213,581-2.68%
2024-01-03SaleCHIEF FINANCIAL OFFICER
12,000
0.0171%
$20.00$240,000-0.65%
2024-01-02SaleCHIEF ACCOUNTING OFFICER
16,670
0.0245%
$19.17$319,564+7.60%
2023-12-19SaleCHIEF ACCOUNTING OFFICER
9,316
0.0133%
$19.13$178,215+4.59%
2023-12-07SaleCHIEF MEDICAL OFFICER
28,600
0.0801%
$17.65$504,758+11.69%

Insider Historical Profitability

4.3%
Patel Sanj KCHAIRMAN & CEO
63012
0.0873%
$23.02110
BAKER BROS. ADVISORS LP
2700597
3.7404%
$23.0220+4.3%
Cormorant Asset Management, LPdirector
900443
1.2471%
$23.0210+4.3%
Flynn James E10 percent owner
843352
1.1681%
$23.0210+4.3%
Beetham Thomas W.EVP & Chief Legal Officer
297523
0.4121%
$23.0216

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$82.75M5.914.19M+31.86%+$19.99M<0.01
Fairmount Funds Management LLC$63.23M4.523.2M+11.15%+$6.35M6.89
Hillhouse Capital Advisors Ltd$61.87M4.423.14MNew+$61.87M1.35
The Vanguard Group$58.83M4.22.98M+0.56%+$327,419.35<0.01
Baker Bros Advisors LP$55.43M3.962.81M0%+$00.4
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.